Performance data for the three stool antigen kits for group A (n=72): patients who had received no interacting medications in the past 4 weeks
| Group A | Number of equivocals | Number of true positives | Number of true negatives | Sensitivity | Specificity | NPV | PPV |
|---|---|---|---|---|---|---|---|
| Gold standard diagnosis | 0 | 25 | 47 | 100% | 100% | ||
| Premier Platinum HpSA† | 8 | 14 | 38 | 63.6% (40.4% to 82.8%) | 92.6% (80.1% to 98.5%) | 82.6% (68.6% to 92.2%) | 82.4% (56.6% to 96.2%) |
| Femtolab Cnx | 0 | 22 | 46 | 88.0% (68.8% to 97.5%) | 97.6% (88.7% to 99.9%) | 93.6% (83.1% to 98.7%) | 95.7% (78.1% to 99.9%) |
| Dia.Pro Hp Ag | 0 | 14 | 46 | 56.0% (34.9% to 75.9%) | 97.6% (88.7% to 99.9%) | 80.7% (68.1% to 90.0%) | 93.6% (68.1% to 99.8%) |
| For sensitivity, specificity, NPV, and PPV the percentages are given with 95% confidence intervals in parenthesis. | |||||||
| Gold standard diagnosis: patients were considered Helicobacter pylori positive if culture alone was positive or if two of three invasive tests were positive; †1 less stool was tested with this kit. | |||||||
| NPV, negative predictive value; PPV, positive predictive value. | |||||||